Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Exchange Rate Effect (2017 - 2022)

Protagonist Therapeutics (PTGX) has disclosed Exchange Rate Effect for 6 consecutive years, with $75000.0 as the latest value for Q4 2022.

  • Quarterly Exchange Rate Effect rose 240.91% to $75000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$90000.0 through Dec 2022, up 28.57% year-over-year, with the annual reading at -$90000.0 for FY2022, 28.57% up from the prior year.
  • Exchange Rate Effect hit $75000.0 in Q4 2022 for Protagonist Therapeutics, up from -$175000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $123000.0 in Q3 2020 to a low of -$175000.0 in Q3 2022.
  • Historically, Exchange Rate Effect has averaged -$14666.7 across 5 years, with a median of -$14000.0 in 2019.
  • Biggest YoY gain for Exchange Rate Effect was 1244.44% in 2020; the steepest drop was 1000.0% in 2020.
  • Year by year, Exchange Rate Effect stood at -$87000.0 in 2018, then crashed by 43.68% to -$125000.0 in 2019, then skyrocketed by 116.8% to $21000.0 in 2020, then rose by 4.76% to $22000.0 in 2021, then soared by 240.91% to $75000.0 in 2022.
  • Business Quant data shows Exchange Rate Effect for PTGX at $75000.0 in Q4 2022, -$175000.0 in Q3 2022, and -$19000.0 in Q2 2022.